CD14启动子-260C/T基因多态性与胃癌易感性的Meta分析  

Association between CD14 Promoter-260 C/T Gene Polymorphism and Susceptibility of Gastric Cancer: a Meta-Analysis

作　　者：王明珠[1] 谭诗云[1] 李明[1] 郭芳[1] 舒咏翔 

机构地区：[1]武汉大学人民医院消化内科,430060

出　　处：《医学研究杂志》2015年第6期42-46,共5页Journal of Medical Research

基　　金：湖北省自然科学基金资助项目(ZRZ0050)

摘　　要：目的 CD14启动子-260C/T基因多态性与胃癌易感性的关系已被广为研究,但是其结果并不尽相同.为了更精确评估二者的关系,笔者进行了Meta分析.方法 计算机全面检索PubMed、Medline、EMbase、CBM、CNKI、万方和维普等数据库,并辅以手检.检索时间从建库截至2015年1月1日,收集CD14启动子-260 C/T基因多态性与胃癌易感性病例对照研究.采用RevMan 5.2软件计算合并效用量OR及其95％ CI,采用Stata 12.0合成漏斗图.结果 共纳入10个研究,其中病例组2365例,对照组3497例.Meta分析发现,在4个遗传模型中,CD14启动子-260C/T基因多态性与胃癌风险的相关性差异均无统计学意义（显性模型：OR=1.07,95％ CI：0.83 ～1.39;隐形模型：OR=1.08,95％ CI：0.89 ～ 1.30;TT vs CC模型OR=1.11,95％ CI：0.79～1.56;CTvsCC模型：OR=1.06,95％CI：0.83 ～ 1.35）.进一步以种族及对照来源行分层分析,亦未发现CD14启动子-260 C/T基因多态性与胃癌风险存在相关性（显性模型：HB对照源：OR=1.02,95％CI：0.63 ～ 1.65,PB对照源：OR=1.12,95％CI：0.85 ～ 1.49;亚洲人：OR=1.12,95％CI：0.73 ～ 1.71;白种人：OR=1.02,95％CI：0.80 ～1.30）.结论 CD14启动子-260C/T基因多态性与胃癌易感性无关,基因型TT和CT＋ TT并不增加罹患胃癌的风险.Objective The CD14 promoter -260 C/T gene polymorphism have been shown to confer genetic susceptibility to gastric cancer, but the results are inconsistent. In order to accomplish a more precise estimation of the relationship, a meta analysis was per- formed. Methods All eligible case - control studies published up to Jan. 2015 were identified by searching PubMed, Medline, EMbase, BM, CNKI, VIP , etc. Meta - analysis was performed by RevMan 5.2 and stata 12.0 software. Results A total of 10 studies including 2365 cases of patients and 3497eases of controls. There was no significant association between CD14 promoter - 260 C/T gene polymor- phlsm and gastric cancer susceptibility was found in overall meta - analysis （ dominant models- OR = 1.07,95% CI：0.83 - 1.39 ; reces- sive models：OR=1.08,95%CI：0.89-1.30; TTvs CC models： OR=1.11,95%CI：0.79-1.56;CT vs CC models：OR=1.06,95% CI：0.83 -1.35 ）. In subgroup analyses of source of controls and ethnicity, we didn＇t found a significant association between CD14 pro- moter - 260 C/T gene polymorphism and gastric cancer susceptibility （ dominant models ： HB source ： OR = 1.02,95% CI：0.63 - 1.65, PB source：OR = 1.12, 95% CI：0.85 - 1.49; Caucasian：OR = 1.02,95% CI：0.80 - 1.30, Asian：OR = 1.12, 95% CI：0.73 - 1.71 ）. Conclusion The CD14 promoter - 260 C/T gene polymorphism was not related to susceptibility of gastric cancer, and genotype TT and CT ＋ TT didn＇t increase the risks of suffering from gastric cancer.

关 键 词：CD14-260C/T 基因多态性 胃癌 META分析 

分 类 号：R735.2[医药卫生—肿瘤]